proline has been researched along with cycloanthranilylproline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, M; Ishibashi, M; Komiyama, K; Nakatani, S; Yamamoto, Y | 1 |
| Hasegawa, H; Hayashi, M; Ishibashi, M; Izuhara, T; Kamihira, S; Komiyama, K; Masuda, M; Sugahara, K; Sunazuka, T; Takasu, N; Tomonaga, M; Tsukasaki, K; Tsuruda, K; Yamada, Y | 1 |
| Ishibashi, M | 1 |
1 review(s) available for proline and cycloanthranilylproline
| Article | Year |
|---|---|
[Study on myxomycetes as a new source of bioactive natural products].
Topics: Animals; Benzofurans; Drug Design; Glycosides; Lactones; Myxomycetes; Naphthoquinones; Polyenes; Proline; Pyrroloiminoquinones; Sterols | 2007 |
1 trial(s) available for proline and cycloanthranilylproline
| Article | Year |
|---|---|
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production.
Topics: Apoptosis; Cell Line, Transformed; Cyclooxygenase 2; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia; Neoplasm Proteins; PPAR gamma; Proline; Prostaglandin D2; TNF-Related Apoptosis-Inducing Ligand | 2007 |
1 other study(ies) available for proline and cycloanthranilylproline
| Article | Year |
|---|---|
Cycloanthranilylproline-derived constituents from a myxomycete Fuligo candida.
Topics: Isatis; Japan; Molecular Structure; Myxomycetes; Nuclear Magnetic Resonance, Biomolecular; Proline | 2004 |